LONDON, UK: Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announced that early results on the two-month-old direct to consumer program have exceeded the Board’s initial expectations.
The company has introduced a three-prong direct sales, leasing and short-term rental program for its established X-PLOR® device that has been well received by customers. Recognising a significant need and opportunity to provide portable oxygen concentrators to customers not previously served by durable medical equipment companies, the Company designed a program intended to capture a meaningful underserved population of people suffering from lung disease.
The company sees this program expanding significantly with the launch of the DISCOV-R™ portable oxygen concentrator.
Bob Fary, Senior Vice President Sales and Marketing Belluscura plc, commented: “I am very excited about the new direct-to consumer sales program. We have identified a potentially significant sales opportunity that not only benefits the Company, but underrepresented patients as well.”